Quick Win By The Algorithm: Arrowhead Pharmaceuticals, Inc. Reports Third Quarter 2017 Fiscal Results

Quick Win By The Algorithm

On August 13th, 2017, I Know First issued a bullish 1-month forecast for Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR). The forecast showed a signal of 29.27 and a predictability of 0.15. In accordance with the forecast, the company’s stock produced a return of 91.85% over this period, solidifying another quick win by the I Know First algorithm.

Founded in 1989 and headquartered in California, Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc.

Arrowhead Pharmaceuticals has reported their fiscal results for the third quarter of 2017. The company continued to develop treatments for chronic hepatitis B infection and also for liver disease associated with AATD, in the first quarter of 2017.  In April, ARWR presented at The International Liver Congress the positive results achieved by those studies.

Moreover, ARWR also continues progressing with its preclinical candidates. Thus, ARWR increased its revenue to $9,342,498 during the three months period ended in June 30, 2017, from $39,583 in the previous year. The increasing in ARWR’s revenue allowed the reductions in the net losses and diluted losses per share. During the same three months ended in June 30, 2017, net losses were decreased to $5.5 million from $19.4 million one year before and net loss per share dropped to $0.07 from $0.32.

Current I Know First subscribers received this bullish ARWR forecast on August 13th, 2017

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.